Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 1 of 61 FARADAY PHARMACEUTICALS , INC.  
FDY -5301 -201-US 
 
Study Title:  A Phase 2A, Randomized, Double -Blind, Placebo -
Controlled, Multi -Center Study of Intravenous FDY -5301 in 
Acute Myocardial Infarction  
Study Drug:  FDY -5301  
Protocol Numbe r: FDY -5301 -201-US 
Drug Development 
Phase:  2A 
Sponsor:  Faraday Pharmaceuticals, Inc.  
[ADDRESS_194197] E, Suite 560  
Seattle, WA [ZIP_CODE]  
(206) 492 -5310  
Protocol Version/Date  Version  2 / May 21, [ADDRESS_194198] of the clinical investigation without the prior written consent of Faraday Pharmaceuticals, Inc.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 3 of 61 INVESTIGATOR’S AGREE MENT  
I have read the attached protocol entitled “ A Phase 2A, Randomized, Double -Blind, Placebo -Controlled, Multi -Center Study of 
Intravenous FDY -5301 in Acute Myocardial Infarction ” dated [ADDRESS_194199] of the clinical investigation without the prior written consent of Faraday Pharmaceuticals, Inc.  
   
Signature    
   
[INVESTIGATOR_678]   [CONTACT_1782] (DD Month YYYY)  
 
 
 
 
 
 
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194200] to critical review and has been approved by [CONTACT_167103].  
   
Signature    
[CONTACT_167137]   21 May 2018  
Chief Medical Officer    Date (DD Month YYYY)  

Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 5 of 61 1 SYNOPSIS  
Name [CONTACT_790]/Company:  Faraday Pharmaceuticals, Inc.  
[ADDRESS_194201]:  FDY -5301  
Name [CONTACT_3261]:  Sodium Iodide (NaI)  
Title of Study:  A Phase 2A, Randomized, Double -Blind, Placebo -Controlled, Multi -Center Study of 
Intravenous FDY -5301 in Acute Myocardial Infarction  
Principal Investigator:  [INVESTIGATOR_167083]-Investigator (s): TBD  
Estimated date first patient 
enrolled:  3Q, [ADDRESS_194202] patient 
completed:  2Q, 2018  
Phase of development:  Phase 2A safety  and efficacy  study  
Purpose:  To evaluate the safety , efficacy  and pharmacokinetics (PK) of [ADDRESS_194203] -segment elevation myocardial 
infarction (STEMI) undergoing  percutaneous coronary intervention  (PCI). 
Primary Outcome:  The primary outcome for this study  will be the combined number and incidence  rate of 
several arrhythmias  of interest  for [ADDRESS_194204] PCI by [CONTACT_167104], Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 6 of 61 wearable patch devices.  
Secondary Outcomes:  Infarct size parameters will be assessed by [CONTACT_159087] ( CMR ) at 72 +/ -[ADDRESS_194205]-study drug ; the following will be compared between 
groups; i nfarct size as a propor tion of ventricular volume  (INF/VV) , myocardial salvage 
index (MSI)  and absolute  myocardial infarction  size (INF ). 
 
The p roportion of patients with ST -segment resolution at [ADDRESS_194206] treatment  
 
Persistent arrhythmias at 30 days and 3 months  
 
Measures of cardiac function  by [CONTACT_167105] -diastolic volume (EDV), end -systolic 
volume (ESV), fractional shortening (FS) and ejection fraction (EF ) at discharge and 3 
months  
 
Biomarkers  of cardiac injury, inflammation  and remodeling  out to 3 months of follow u p 
 
Cardiac related adverse events including the development of heart failure  out to 3 months of 
follow up  
 
Incidence of all cause and cardiac mortality out to 6 months of follow up  
 
Additional Safety and tolerability:  Physical examination including vital signs, clinical chemistry, hematology and thyroid 
function tests  will be monitored . Adverse Events (AEs) and Serious Adverse Events (SAEs) 
will be recorded. [ADDRESS_194207] basel ine.  
Pharmacokinetics : Plasma iodide samples will be taken to estimate C max, AUC , Tmax and T1/2. 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 7 of 61 Methodology:  This is a Phase 2A, randomized, double -blind, placebo -controlled, multi -center st udy that 
will evaluate  safety, efficacy and PK of FDY -[ADDRESS_194208] is unavailable 
then mortality status will be obtained from physician/investigator records.  
Number of patients : Up to 1 60 patients  
Diagnosis and main criteria for 
inclusion:  1. 18-[ADDRESS_194209] STEMI, based on clinical and ECG 
criteria (ST -elevation at the J -point in two contiguous leads with the cut -off points: 
≥0.2 millivolt (mV) in men or ≥0.15 mV in women in leads V2 -V3 and/or ≥0.1 mV in 
other leads) within 12 hours of symptom onset  
4. Written i nformed consent  prior to study participation  (either by [CONTACT_28246] a 
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194210])  
Exclusion Criteria:  1. Previous myocardial infarction  
2. Left bundle branch block (LBBB)  
3. Previous coronary artery by[CONTACT_10956]  (CABG)  
4. Major hemodynamic instability or uncontrolled ventricular arrhythmia s 
5. Known contraindication  to CMR ( e.g. pacemaker)  
6. Patients with known  thyroid disease , or known a llergy to iodide  
7. Subjects with past or current renal impairment requiring dialys is 
8. Pregnant or females of childbearing potential  
9. Body weight > 12 0 kg or Body Mass Index (BMI) >  35 kg/m2  
10. Use of investigational drugs or devices within [ADDRESS_194211], dosage and 
mode of administration:  FDY -5301 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or placebo will be administered intravenously  
(IV) by [CONTACT_167106] 5 minutes prior to coronary artery reperfusion.  
Duration of treatment:  
  Treatment is a single IV bolus administration of study drug. Each subject will be involved up 
to 6 months from screening until study exit.  
Reference therapy, dosage and 
mode of administration:  Placebo (normal saline  for injection). Placebo will be indistinguishable from FDY -5301.  
Statistical methods:  The primary outcome for this study  will be t he combined number  and incidence rate of 
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194212]-study drug . 
These arrhythmias including ventricular fibrillation, sustained  ventricular tachycardia  (≥125 
BPM, ≥ 30 seconds), non-sustained ventricular tachycardia (≥ 125 BPM, ≥ 16 beats, < 30 
seconds) and high degree AV block ( 2nd or 3rd degree, ≥ 8  beats) were chosen because they 
are significant prognostic indicators of depressed left ventricular ejection fraction and cardiac 
death [ 1]. The combined number of arrhythmic events in each group will be calculated along 
with the arrhythmia incidence rate defined as the percentage of patients in each group 
experiencing at least one of the defined arrhythmias of interest.  
An exploratory  sub-analysis will be conducted to determine the number and incidence  rate of 
each separate arrhythmia type per dose group.  
Little data exists on the incidence of arrhythmias that occur over an extended period of time 
following AMI and monitoring strategies for this type of assessment have not been optimized 
in a clinical trial  setting. The primary goal of our study is to characterize the occurrence  of 
arrhythmias in this patient population for [ADDRESS_194213] significant differences in efficacy measures across groups. Estimating a drop -out rate 
of 50%, we will need to enroll up to 1 60 patients in order to obtain a final total  sample size of 
80 patients . A final sample size of 80 patients will provide  80% power to detect a 37% 
reduction  in INF/VV assuming an SD of 10%, a 24% increase in MSI assuming an  SD of 
20% and a 39% reduction in Troponin AUC with an SD of 60%. Equal variance was 
assumed among groups with an unbalanced allocation of patients to placebo (n=20) and 
combined FDY -5301 treatment groups (n=60).  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 10 of 61 Exploratory e fficacy outcomes will include : 
Between group comparisons of infarct size as a proportion of ventricular volume ( INF/VV), 
the myocardial salvage index (MSI) , and absolute MI size ( INF) at 72 +/- [ADDRESS_194214] PCI . 
In addition to the measurement of safety and efficacy parameters in this study, serum 
biomarker levels of cardiac injury , inflammation and remodeling will also be assessed .  
After the 14 day follow up visit  to the clinic , analysis of all subjects’ data will be collected 
and analyzed for safety (arrhythmias) and early efficacy outcomes . 
After the 3 month  follow up visit,  analysis of efficacy outcomes including final MSI, 
INF/VV, INF  parameters and car diac function including EDV, ESV, FS and EF will be 
analyzed. All remaining assessments will be analyzed at the conclusion of the  study .  
For P K analysis, Cmax, AUC , Tmax and T1/2 will be calculated for each dose based on plasma 
iodide levels.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 11 of 61 Document H istory  
Protocol Number : FDY -5301 -201  
Original Protocol 
Date:  August 30, 2017   
Amendment Number  Amendment Date  Explanation of Changes  
   
   
   
 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 12 of 61 Table 1: Emergency Contact [CONTACT_167107] (CRO)  
Role in Study  Name  [CONTACT_167138], Inc.,   
FDY -[ADDRESS_194215] OF ABBREVIATION S AND DEFINITION OF TERMS  ...........................  17 
3 INTRODUCTION ................................ ................................ ................................ ...... 20 
3.1 Disease  ................................ ................................ ................................ .........................  20 
3.2 FDY -5301 Background  ................................ ................................ ................................  20 
3.3 Rationale  ................................ ................................ ................................ ......................  21 
4 TRIAL OBJECTIVES AND  PURPOSE  ................................ ................................ . 22 
4.1 Primary Outcome  ................................ ................................ ................................ .........  22 
4.2 Seco ndary Outcomes  ................................ ................................ ................................ ... 22 
5 INVESTIGATIONAL PLAN  ................................ ................................ ...................  24 
5.1 Overall Study Design and Plan: Description  ................................ ...............................  24 
5.2 Number of Centers/Subjects  ................................ ................................ ........................  24 
5.3 Estimated Study Duration  ................................ ................................ ............................  25 
5.4 Assignment to Study  ................................ ................................ ................................ .... 25 
5.5 Schedule of Assessments  ................................ ................................ .............................  25 
5.5.1  Screening (Day 1 – Prior to PCI)  ................................ ................................ .................  25 
5.5.2  Treatment Day 1 – in Cardiac Catheterization Lab and Recovery  ..............................  26 
5.5.3  Day 2 (24 hours +/ - [ADDRESS_194216] -study drug)  ................................ ..............................  27 
5.5.4  Day 3 (48 hours +/ - [ADDRESS_194217] -study drug)  ................................ ..............................  [ADDRESS_194218] CMR (72 hours +/ - [ADDRESS_194219] -study drug)  ................................ ....................  27 
5.5.6  Follow -up 14 days (+/ - [ADDRESS_194220]  drug)  ................................ ................................ .... 28 
5.5.7  Follow -up 30 days (+/ - [ADDRESS_194221] drug)  ................................ ................................ ... 28 
5.5.8  Follow -up 3 months (+/ - [ADDRESS_194222] drug)  ................................ ...............................  28 
5.5.9  Follow -up 6 months or early termination (+/ - [ADDRESS_194223] drug)  ..............................  [ADDRESS_194224] Withdrawal Criteria  ................................ ................................ ........................  32 
6.4 Early Termination Visit  ................................ ................................ ...............................  33 
7 STUDY TREATMENTS  ................................ ................................ ...........................  34 
7.1 Descri ption of Study Drug  ................................ ................................ ...........................  34 
7.2 Concomitant Medications  ................................ ................................ ............................  34 
7.3 Randomization and Blinding  ................................ ................................ .......................  34 
8 STUDY DRUG MATERIALS  AND MANAGEMENT  ................................ .........  35 
8.1 Study Drug  ................................ ................................ ................................ ...................  35 
8.2 Study Drug  Packaging and Labeling  ................................ ................................ ...........  35 
8.3 Study Drug Storage  ................................ ................................ ................................ ...... 35 
8.4 Study Drug Preparation ................................ ................................ ................................  35 
8.5 Administration  ................................ ................................ ................................ .............  36 
8.6 Study Drug Accountability  ................................ ................................ ..........................  36 
8.7 Study Drug Handling and Disposal  ................................ ................................ .............  36 
9 REPLACEMENT OF SUBJE CTS  ................................ ................................ ...........  38 
10 CMR PROTOCOL  ................................ ................................ ................................ .... 39 
11 STUDY OUTCOMES  ................................ ................................ ................................  40 
12 ASSESSMENT OF PHARMA COKINETICS, TROPONIN  AND LABORATORY SAFET Y MEASURES  42 
12.1  Pharmacokinetics: Blood Iodide Levels  ................................ ................................ ...... 42 
12.1.1  Pharmacokinetic Evaluation  ................................ ................................ ........................  42 
12.2  General Safety  ................................ ................................ ................................ ..............  42 
12.2.1  ECGs  ................................ ................................ ................................ ............................  42 
12.2.2  Biochemistry  ................................ ................................ ................................ ................  43 
12.2.3  Hematology  ................................ ................................ ................................ ..................  43 
12.2.4  Troponin Levels  ................................ ................................ ................................ ...........  43 
12.2.5  Other Biomarkers of Cardiac Injury and Inflammation  ................................ ...............  43 
12.3  Laboratory Certification and Reference Ranges  ................................ ..........................  43 
13 SAFETY: ADVERSE EVEN TS ................................ ................................ ...............  45 
13.1 Definitions ................................ ................................ ................................ ....................  45 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 15 of 61 13.2  Relationship to Study Drug  ................................ ................................ ..........................  45 
13.3  Intensity of Adverse Events  ................................ ................................ .........................  46 
13.4  Reporting Serious Adverse Events  ................................ ................................ ..............  46 
14 STATISTICS  ................................ ................................ ................................ ..............  48 
14.1  Study Design  ................................ ................................ ................................ ................  48 
14.1.1  General Approach/Considerations  ................................ ................................ ...............  48 
14.1.2  Populations  ................................ ................................ ................................ ...................  48 
14.1.3  Study Outcomes  ................................ ................................ ................................ ...........  48 
14.1.4  Sample Size Estimation  ................................ ................................ ...............................  49 
14.1.5  Interim and Final Analyses  ................................ ................................ ..........................  49 
14.1.6  General Analysis of Safety and Efficacy Outcomes  ................................ ....................  50 
14.1.7  Pharmacokinetic Data Analysis  ................................ ................................ ...................  50 
15 ACCESS TO SOURCE DAT A/DOCUMENTS  ................................ ......................  [ADDRESS_194225] (IRB) / Independent Ethics Committee (IEC)  .................  [ADDRESS_194226] OF TABLES  
Table 1: Emergency Contact [CONTACT_7171] ................................ ................................ .....................  12 
Table 2: Study Design and Schedule of Assessments  ................................ ................................ .. 30 
Table 3: Relationship of AE to Study Drug or Trial -Related Procedures  ................................ .... [ADDRESS_194227] OF FIGURES  
Figure 1: Study Diagram  ................................ ................................ ................................ ...............  [ADDRESS_194228]  aspartate transaminase  
AUC  area under (concentration -time) curve  
BMI  body mass index  
BP blood pressure  
CL Clearance  
Cmax maximal drug concentration  
CMR  cardiac magnetic resonance  
CRF  case report form  
DLT  dose limiting toxicity  
ECG  Electrocardiogram  
EDV  end diastolic volume  
ESV  end systolic volume  
EF ejection fraction  
FS fractional shortening  
GCP  good clinical practice  
GLP  good laboratory practice  
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194229] Term  Explanation  
RR respi[INVESTIGATOR_167084]  
T1/[ADDRESS_194230] line of therapy for STEMI includes coronary artery reperfusion by [CONTACT_167108] (angioplasty). While clearly effective, 
it does  not address the issue of “reperfusion injury”, a secondary damage that develops due to the revascularization of the previousl y 
ischemic myocardial tissue. Even though angioplasty ha s dramatically improved the survival rate, the goal of developi[INVESTIGATOR_167085] -[ADDRESS_194231] size, and consequent ly improve short and longer -term outcomes after AMI/reperfusion.  
3.[ADDRESS_194232] (herein after referred to as FDY -5301) is sodium iodide formulated as an isotonic solution in a single us e vial for 
intravenous administration. The solution has a pH between 7.0 and 9.5. A monograph for sodium iodide is listed in the current  United 
States Pharmacopoeia (USP). The chemical formula of sodium iodide is NaI.  
The route of administration is by [CONTACT_167109] (IV) injection .  
As discussed in the  Investigators Brochure  (IB), the nonclinical safety assessment of FDY -5301 includes pi[INVESTIGATOR_167086] ( GLP ) 7 and 14 day IV repeat dose toxicity studies, pharmacokinetic studies, local tolera bility  studies, a series of in vitro and 
in vivo safety pharmacology, in vitro hemocompatibility, in vitro cytochrome P450 inhibition, in vitro protein binding, and 
genotoxicity studies conducted in accordance with International Conference on Harmonization  (ICH) guidelines . 
An IV bolus single dose toxicity study in rats showed that FDY -5301 was associated with no mortality in animals receiving bolus 
injections of up to 1000 mg/kg. Adverse clinical signs were not observed in either gender.  
In rats, no signs of toxicity were observed at doses up to 74 mg/kg given daily IV for 14 days. In beagle dogs the NOAEL was 
established at 20  mg/kg for 7 days dosing. The observed DLT at 40 mg/kg was reversible gastro -intestinal inflammation.   
Safety pharmacology studies included an in vitro hERG  K+ ion channel assay, a CNS safety pharmacology study (general signs and 
behavior) in rats, a pulmonary safety pharmacology study in rats, and a cardiovascular safety pharmacology study in dogs. Ove rall, the 
results of these studi es show that at the dosing regimen and at expected systemic exposures of FDY -5301 to be achieved in humans, 
no adverse effects are anticipated to occur in any of the major organ systems tested.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 21 of 61 FDY -5301 was found not to be mutagenic in the bacterial rever se mutation assay.  
Other studies with FDY -5301 show that the formulation to be used for clinical trials is not expected to cause local perivenous 
irritation. In addition, it does not exhibit protein binding  nor does it inhibit cytochrome P450 enzymatic ac tivity . FDY -5301 was also 
shown to be compatible with human, dog, and rat serum, plasma, and whole blood.  
As well as the extensive experience and known safety of orally administered iodide, it has been used intravenously in humans to 
manage thyrotoxic cris is. 
Faraday has conducted a phase 1 single ascending dose study in healthy volunteer subjects at intravenous doses of up to 10 mg/kg. No  
significant  adverse events were detected, including biochemical measures of thyroid function. The anticipated therapeut ic dose is 
likely in the range of 0.5 to 2.0 mg/kg  based on nonclinical studies and human PK data . 
3.[ADDRESS_194233] ye t been conducted with FDY -5301 . The anticipated human effective dose based on preclinical data is from 0.5 to 2.0 
mg/kg. The study outlined herein is designed to assess the safety , efficacy  and PK of FDY -[ADDRESS_194234] STEMI about to 
undergo PCI.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 22 of 61 4 TRIAL OBJECTIVES AND  PURPOSE  
The purpose of this study is to evaluate the safety , efficacy, and pharmacokinetics  (PK) of three dose levels  of FDY -[ADDRESS_194235] -study drug . These arrhythmias including ventricular fibrillation, sustained  ventricular 
tachycardia  (≥125 BPM, ≥ 30 seconds), non-sustained ventricular tachycardia (≥ 125 BPM, ≥ 16 beats, < 30 seconds) and high degree 
AV block ( 2nd or 3rd degree, ≥ 8 beats) were chosen because they are significant prognostic indicators of depressed left ventricular 
ejection fraction and cardiac death [ 1]. The combined number of arrhythmic events in each group will be calculated along with the 
arrhythmi a incidence rate defined as the percentage of patients in each group experiencing at least one of the defined arrhythmias of 
interest.  
An exploratory sub -analysis will be conducted to determine the number and incidence rate of each separate arrhythmia typ e per dose 
group.  
Continuous cardiac monitoring will occur for [ADDRESS_194236] size parameters will be assessed by [CONTACT_167110] 72 +/ - 24 hours  and 3 months ; the following will be compared between groups; 
infarct size as a propor tion of ventricular volume  (INF/VV) , myocardial salvage index (MSI) and a bsolute MI size .  
 
• The p roportion of patients with ST -segment resolution at [ADDRESS_194237] study drug  
• Serum levels of troponin calculated as AUC  0-[ADDRESS_194238] -study drug  
• Persistent arrhythmias at 30 days and 3 months  
• Measures of cardiac function by [CONTACT_167105] -diastolic volume (EDV), end -systolic volume (ESV), fractional 
shortening (FS) and ejection fraction (EF).   
• Serum biomarkers of cardiac in jury, inflammation  and remodeling  
•       Cardiac -related adverse events including the development of heart failure  out to 3 months of follow up  
• Incidence of all cause and cardiac mortality out to 6 months of follow up -to be assessed by [CONTACT_167111], Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 23 of 61 patient is unavailable, by [CONTACT_167112]/investigator . 
 
Safety and Tolerability:  
Physical examination including vital signs, laboratory measures to include clinical chemistry, hematology and thyroid function tests  
will be performed . Adverse Events (AEs) and Serious Adverse Events (SAEs) will be recorded.  
[ADDRESS_194239] baseline .  
Pharmacokinetics:  
Plasma iodide levels will be measured in each patient. The concentration -time profile of plasma  iodide will be derived for each of the 
groups. The pharmacokinetics of iodide will be described as area under the concentration versus time curve (AUC), the maximal  
concentration (C max) and the time (T max) when the maximal concentration is achieved. The t erminal half -life (T 1/2), the total body 
clearance (CL), and the volume of distribution (V) will also be derived.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 24 of 61 5 INVESTIGATIONAL PLAN  
5.1 Overall Study Design  and Plan: Description  
This is a Phase 2A, Randomized, Double -Blind, Placebo -Controlled, Multi -Center  Study of Intravenous FDY -5301 in Acute 
Myocardial Infarction (AMI).  
Study subjects will be recruited at each investigational site (or referred to the investigative site from another institution ) for treatment 
of first STEMI. Subjects will be screened and written informed  consent will be obtained prior to initiation of any study related 
procedures in those subjects who meet the inclusion and exclusion criteria for the study.  
Up to 1 60 patients will be randomized to receive either FDY -5301 at doses of 0.5 m g/kg, 1.0mg/kg, 2.0mg/kg or placebo.  
STEMI diagnosis will be made based on clinical and ECG findings including: subjects presenting with ≥ [ADDRESS_194240] -segment elevation of ≥ [ADDRESS_194241].  
5.2 Number of Centers/ Subjects  
This study will be conducted at up to [ADDRESS_194242]’s participation will 
be up to [ADDRESS_194243] . Information from patients who are screened and do not meet the study entry 
criteria will be entered into a screening log. Once assigned, screening numbers for any screening failures, untreated, non -evaluable, or 
discontinued subjects will not be re -used.  
All subjects who satisfy the Inclusion/Exclusion criteria will be randomly allocated to one of four treatment groups (FDY -5301 0.5 
mg/kg, 1.0 mg/kg, 2.0 mg/kg, or placebo) . 
5.[ADDRESS_194244] of Screening/Treatment (Day 1), evaluations at Day 2 and Day 3 , and follow -up visits at 14 
days, 30 days  and 3 months , and a telephone  call at 6 months (see Figure 1). 
5.5.1 Screening (Day 1 – Prior to PCI ) 
1. Prospective subjects will present to the hospi[INVESTIGATOR_167087] ≥ [ADDRESS_194245] -segment elevation of ≥ [ADDRESS_194246] the purpose of the study and its procedures and risks explained  
 
Subjects, or their legally appointed r epresentative (LAR), must give written informed consent before any screening procedures can be 
started. During screening the following procedures will be conducted for all subjects  if possible  to determine study eligibility  (some 
medical history may be gathered after treatment if not an exclusion criterion) : 
• Inclusion/Exclusion criteria will be documented  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 26 of 61 • 12-lead ECG  for STEMI diagnosis  
• Demographics (age, gender, smoking status)  
• General medical/surgical history (co -morbiditi es, duration of symptoms, and prior and present therapi[INVESTIGATOR_014])  
• Study specific medical/surgical history and concomitant conditions, especially thyroid disorders  
• Prior and current medications taken within two weeks prior to study drug administration  
• Physical exa mination  
• Vital signs including: temperature, pulse, respi[INVESTIGATOR_697], blood pressure  
• Height and weight: In the event that the body weight is not available at time of study drug dosing, the subject’s last 
reported weight or estimated weight will be used fo r study drug dosage calculation.  
5.5.2 Treatment Day 1 – in Cardiac Catheterization Lab and Recovery  
• Random allocation to study drug (once screening is complete and consent is obtained  either from the subject or a legally 
authorized representative of the subjec t, randomization must occur to ensure study drug is given by [CONTACT_167113] [ADDRESS_194247]  5 minutes prior to reperfusion)  
• Study drug administration  
• Vital signs (pulse, respi[INVESTIGATOR_697], blood pressure) will be recorded every 15 minutes after study drug  for an hour , then 
hourly for another 4 hours . There is a +/ - 10 minute window on all vital sign collections  
• Blood sampling to assess anticoagulation  during the procedure  (INR)  
• Documentation of peri -procedural arrhythmias by [CONTACT_167114] 12 -lead ECG  
• Continuous ECG monitoring will commence post procedure as soon as the [ADDRESS_194248] study drug1 
• Standard [ADDRESS_194249] segment resolution (3 strips at each time point)  
• Blood samples for troponin T will be obtained (see time points in Section 12) 
• PK blood sampling (see time points in  Section  12) 
• Blood sample to assess biomarkers of cardiac injury and inflammation (see time points in Section 12) 
• Laboratory  safety  tests (as outl ined in Section 12) 
• Recording of concomitant medications  
• Recording of any AEs  
• If study informed consent was given by [CONTACT_423]’s legally authorized representative for study enrollment, the subject will  
be pro vided with a modified consent once they are stable  (after investigational drug treatment and STEMI procedure)  and 
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194250]’s ag reement to remain in the clinical trial and proceed with all study related procedures and follow -up. 
[ADDRESS_194251] -study drug. This single -use device will need to be removed 
when  the patient undergoes CMR at 72 +/ - [ADDRESS_194252] -study drug. At that time, a new wearable ECG monitor device will need to  be affixed to  the 
patient.   
5.5.3 Day 2 (24 hours +/ - [ADDRESS_194253]-study drug ) 
• Physical examination and v ital signs (pulse, respi[INVESTIGATOR_697], blood pressure)  
• Laboratory safety tests (as outlined in Section 12) 
• Blood samples for troponin T will be obtained (see time points in Section 12) 
• PK blood sampling (see time points in Section 12) 
• Blood sample to assess biomarkers of cardiac injury and inflammation (see time points in Section 12) 
• Recording of any AEs  
• Concomitant medications  
5.5.4 Day 3 (48 hours +/ - [ADDRESS_194254]-study  drug ) 
• Physic al examination and v ital signs (pulse, respi[INVESTIGATOR_697], blood pressure)  
• Laboratory safety tests (as outlined in Section 12)   
• Blood samples for troponin T will be obtained (see time points in Section 12) 
• Blood sample to as sess biomarkers of cardiac injury and inflammation (see time points in Section 12) 
• Recording of any AEs 
• Concomitant meds  
5.5.[ADDRESS_194255] CMR  (72 hours +/ - [ADDRESS_194256] -study drug)   
• CMR to measure MSI, INF/VV, INF and cardiac function including EDV, ESV, FS and EF . If CMR cannot be completed  
at the time of discharge , the patient  should be encouraged to return for a CMR 48-[ADDRESS_194257] -study drug.   
• Physical examination  and v ital signs (pulse, respi[INVESTIGATOR_697], blood pressure)  (at time of discharge ) 
• Recording of any AEs (at time of discharge ) 
• Concomitant medications  (at time of discharge ) 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 28 of 61 • Discharge with instructions for continuous ECG device  (at time of discharge)[ADDRESS_194258] week ’s data for return to the  clinic at day 14.  
5.5.6 Follow -up 14 days (+/ - [ADDRESS_194259] drug ) 
• Physical examination  and vital signs (pulse, respi[INVESTIGATOR_697], blood pressure)  
• Body weight (kg)  
• Laboratory safety tests (as outlined in Section 12) 
• Recovery of wearable ECG device s and recordings  
• Recording of any AEs  
• Concomitant medications  
5.5.7 Follow -up 30 days (+/ - [ADDRESS_194260] drug ) 
• Physical examination  and v ital signs (pulse, respi[INVESTIGATOR_697], blood pressure ) 
• Body weight (kg)  
• Laboratory  safety  tests (as outlined in Section 12) 
• 12-lead ECG   including rhythm strip to identify persistent arrhythmias  
• Recording of any AEs 
• Concomitant medications  
5.5.8 Follow -up 3 months (+/ - [ADDRESS_194261] drug ) 
• CMR to measure MSI, INF/VV, INF  and cardiac function  including EDV, ESV, FS and EF  
• Recording of any AEs  
• Concomitant medications  
• 12-lead ECG  including rhythm strip to identify persistent arrhythmias  
• Blood sample for analysis of biomarkers of remodeling  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 29 of 61 5.5.9 Follow -up 6 months or early termination (+/- [ADDRESS_194262] drug ) 
Telephone interview with the subject (or relative if subject unable to give his tory) for incidence of all cause and cardiac mortality. If 
subject is unavailable, then physician/investigator records will be source of mortality documentation if available.  
Figure 1: Study Diagram  
 

Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 30 of 61 Table 2: Study Design and Schedule of Assessments  
Activity  Screening  
Day 1  Treatment  
Day 1  Day 2  
(24 +/ - 2 
Hrs ) Day 3  
(48 +/ - 2 
Hrs)  
 First CMR  
(72 +/ -24 
Hrs)  Day 7  
 14 day 
(+/- 2 
days)  30 day  
(+/- 1 
week)  3 month  
(+/- 2 
week s) 6 month/Early 
Termination  
(+/- 4 weeks)  
Inclusion/Exclusion Criteria , IC14 X          
Demographics/Medical History   
 X          
Physical Examination (including Con 
meds)  X  X X X  X X X  
Vital Signs, con meds  X X10 X X X  X X X  
Height and Weight  X          
Safety Laboratory tests   X3 X X   X X   
Troponin T   X4 X X       
Randomization, study drug   X         
ACT during anticoagulation   X         
Document peri -proc. arrhythmias  
  X         
           
Continuous E CG           
Phone call re continuous ECG       X     
12 lead ECG  X X11      X12 X13  
PK-Iodide levels   X5 X X       
Cardiac Biomarkers   X6 X X     X  
CMR      X7    X  
Adverse Events  X X X X X  X X X  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 31 of 61 Follow up phone call or review of 
physician records for all -cause 
mortality        
   X 
Un-blinded Interim Analysis        X8  X9  
3. Safety Lab Sampling  for day 1 : Pre-study drug , [ADDRESS_194263]-study drug   
4. Troponin Sampling  for day 1 : Pre-study drug , and [ADDRESS_194264]-study drug    
5. PK Sampling  for day 1 : Pre-study drug, [ADDRESS_194265] -study drug  
6. Biomarker Sampling  for day 1 : Pre-study drug, 1, [ADDRESS_194266] party 
vendors will not be unblinded to individual patient treatments  
10. Vital signs (pulse, respi[INVESTIGATOR_697], blood pressure) will be recorded every 15 minutes after study drug for an hour, then hourly f or another 4 hours. There is a +/ - 10 
minute window on all vital sign collections  
11. 12 -lead ECG for day 1: at screening for diagn osis of STEMI for inclusion criteria, and  to obtain baseline ST -segment elevation , during PCI treatment to document 
peri-procedural arrhythmias and again at [ADDRESS_194267]’s legal ly authorized representative prior to  study enrollment, the subject will be provided with a modified consent once they are stable 
(after inves tigational drug treatment and STEMI procedure) and in the opi[INVESTIGATOR_167088].  This modified informed consent 
document will cover the subject’s agreement to remain in the clinical trial and proceed with all stu dy related procedures and follow -up. 
 
 
 
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194268] STEMI, based on clinical and ECG criteria 
(ST-elevation at the J -point in tw o contiguous leads with the cut -off points: ≥0.2 millivolt 
(mV) in men or ≥0.15 mV in women in leads V2 -V3 and/or ≥0.1 mV in other leads), within 
12 hours of symptom onset.  
Written informed consent prior to study participation (either by [CONTACT_28246] a l egally 
authorized representative of the subject)  
6.[ADDRESS_194269] Exclusion Criteria  
1. Previous myocardial infarction  
2. Left bundle branch block (LBBB)  
3. Previous coronary artery by[CONTACT_10956] (CABG)  
4. Major hemodynamic instability or uncontrolled ventricular arrhythmias.  
5. Known contraindication to CMR (e.g. pacemaker)  
6. Patients with known thyroid disease, or known allergy to iodide.  
7. Subjects with past or current renal impairment requiring dialysis  
8. Pregnant or females of child  bearing potential  
9. Body weight > 120 kg or Body Mass Index (BMI) > 35 kg/m2  
10. Use of investigational drugs or devices within [ADDRESS_194270]’s rights.  
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194271], subjects who with draw consent or are withdrawn from the study by 
[CONTACT_167115] a follow -up visit (early termination visit) as 
soon as possible and an effort should be made to complete and report the observations as 
thoroughly as possible  up to the date of withdrawal. All information should be reported on the 
applicable CRF.  
6.4 Early Termination Visit  
At any such early termination visit, the procedures scheduled for the six -month follow -up should 
be performed.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 34 of 61 7 STUDY TREATMENT S  
7.1 Description of Study Drug  
FDY -5301 is sodium iodide (chemical formula NaI) administered as an isotonic solution for 
intravenous injection  with a concentration of 7.2 mg/mL . The dosage form of FDY -[ADDRESS_194272] of FDY -5301 (3 dose levels) or placebo.  
All subjects who fulfill all study eligibility criteria will be randomized to receive one of the [ADDRESS_194273]  at 
a concentration of 7.2 mg/mL. T he active ingredient sodium iodide (NaI), and the following 
inactive excipi[INVESTIGATOR_840]: sodium chloride, and water for injection.  
Placebo will be provided as single use 20 mL vials for injection containing sterile saline solution.  
The manufacturing batch (or box number) of investigational product (active drug, placebo) will 
be recorded on each subject’s drug administration case report form  (CSR) . 
8.[ADDRESS_194274] will be manufactured and packaged by [CONTACT_167116], Inc. in accordance with GMP.  
Supply and Return of Drug  
Clinical supplies will be shipped to sites following the completion of study initiation an d receipt 
of Institutional Ethics Approval.  
Labels will be in accordance with all applicable local regulat ions and may includ e: 
• For Investigational Use Only  
• Site identification  
• Subject Number (blank for insertion)  
• Batch (Lot) Number  
• Storage conditions  
• Expi[INVESTIGATOR_167089]  
• Sponsor’s Name  
8.3 Study Drug Storage  
Clinical trial materials will be securely stored as supplied (20 to 25 °C) and should not be 
stored frozen. Direct exposure to sunlight and heat should be avoided.  
The sponsor reserves the right to inspect the drug storage area before and during the trial.  
8.4 Study Drug Preparation  
The formulation has no preservative and is intended for single use only; injection solutions 
should be prepared using aseptic technique and inspected prior to administration. The solutio n 
for injection should be a clear, colorless solution with no particulate matter .  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 36 of 61 A guide will provide detailed instructions for randomization and calculation of dose of drug (or 
volume of placebo) and preparation of the intravenous injection .  Drug administration by [CONTACT_167117] [ADDRESS_194275]’s 
body weight determined on the dose administration day. Preparation of the administered dose 
will be achieved by [CONTACT_167118]  7.2 mg/mL FDY -[ADDRESS_194276] be kept current and should contain:  
• The dates and quantities of investigational product received from Faraday 
Pharmaceuticals, Inc.  
• manufacturing batch or box numbers for product received  
• subject’s identification (subject  number and initials)  
• date and quantity of investigational product dispensed (and remaining, if from 
individual subject drug units)  
• the initials of the dispenser  
• date and quantity of drug returned to the investigator/pharmacy, if appropriate  
At the end of the study, the final investigational product reconciliation statement must be 
completed and provided to Faraday Pharmaceuticals.  
These inventories must be made available for inspection by [CONTACT_167119].  The investigator is 
responsible for the accountability of all used and unused trial supplies.  
8.[ADDRESS_194277] be sent to the Sp onsor. The 
Principal Investigator [INVESTIGATOR_167090].  
Any remaining drug at the end of the study will be disposed of as per sponsor instructions (e .g. at 
the site by [CONTACT_167120]).  
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194278] who receives investigational treatment that does not 
undergo PCI  will be followed up for safety but replaced .  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 39 of 61 10 CMR PROTOCOL  
MRI determination of MSI, MI size, MI/VV , and Cardiac Function  
Cardiac MRI  (CMR)  will be performed at 72 +/ - [ADDRESS_194279] -study drug at the 
study site.   
The 72 hour CMR will include  cine, T2W and LGE imaging  for function, edema and n ecrosis 
respectively . The 3 month CMR will include cine and LGE for function and late scar 
quantification respectively . 
The primary estimate of AAR and hence MSI will be based on CMR imaging of myocardium for 
edema (secondarily  the length of coronary arter y occluded will be document at the time of PCI).  
Cardiac function will be assessed  by [CONTACT_167121], ESV, FS and EF.  
All MRI data will be analyzed at a central core laboratory. Detailed instructions for the conduct 
and interpretation of the CMR will be available  in a separate document, including the parameters 
to be analyzed . 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 40 of 61 11 STUDY OUTCOMES  
Primary Outcome:  The primary outcome for this study will be t he combined number  
and incidence rate of se veral  arrhythmias of interest that occur in 
each group over a [ADDRESS_194280] -study drug .  
These arrhythmias including ventricular fibrillation, sustained  
ventricular tachycardia  (≥125 BPM, ≥ 30 seconds), non-sustained 
ventricular tachycardia (≥ 125 BPM, ≥ 16 beats, < 30 seconds) and 
high degree AV block ( 2nd or 3rd degree, ≥ 8 beats) were chosen 
because they are significant prognostic indicators of depressed left 
ventricular ejection fraction and cardiac death [1].  
The combined number of arrhythmic events in each group will be 
calculated along with the arrhythmia incidence rate defined as the 
percentage of patients in each group experiencing at least one of 
the defined arrhythmias of interest.  
An exploratory sub -analysis will be conducted to determine the 
number and incidence rate of each separ ate arrhythmia type per 
dose group.  
Continuous ECG monitoring will occur from post reperfusion until 
[ADDRESS_194281] study drug by [CONTACT_167122].  
These will be positioned and activated as soon as feasible after 
treatment with study drug  is complete.  
Blinded , standardized central ized interpretation  will be used for 
analysis of arrhythmias  recorded with the wearable device . 
Descriptions of peri -procedural arrhythmias such as reperfusion 
arrhythmias or VF epi[INVESTIGATOR_167091], with particular emphasis on persistent 
arrhythmias.  
Secondary Outcomes:   Infarct size parameters will be assessed by [CONTACT_167110] 72 +/ -
24 hours  and at 3 months; the following will be compared 
between groups; i nfarct size as a propor tion of ventricular 
volume  (INF/VV) , myocardial salvage index (MSI) and 
absolute MI size  
 The p roportion of patients with ST -segment resolution at [ADDRESS_194282] study drug  
 Serum levels of tr oponin calculated as AUC  0-[ADDRESS_194283]-study drug  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 41 of 61  Serum biomarkers of cardiac injury , inflammation  and 
remodeling  out to 3 months of follow up  
 Persistent arrhythmias at 30 days and 3 months  
 Measures of cardiac function by [CONTACT_167123], 
ESV, FS and E F 
 Cardiac -related adverse events including the development 
of heart failure  out to three months of follow up .  
 
Incidence of all-cause and cardiac mortality out to 6 months of 
follow up  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 42 of 61 12 ASSESSMENT OF PHARMA COKINETICS, TROPONIN  AND LABORATORY 
SAFETY MEASURES  
12.1 Pharmacokinetics: Blood Iodide Levels  
12.1.[ADDRESS_194284] the PK samples as close  to the 
time points listed below.  
• Pre-study drug  
• [ADDRESS_194285] deviation (SD) and CV will be calculated at 
each time point. For each dose group, the pharmacokinetic behavior of blood iodide will be 
described as area under the concentration versus time curve (AUC, AUC inf) the maximal 
concentration (C max), the time (T max) when th e maximal concentration is achieved, the apparent 
terminal elimination rate (Kel) and terminal half -life (T 1/2) for each subject. From this 
information, the total body clearance (CL), and the volume of distribution (V) will be derived.  
12.2 General Safety  
Safet y and tolerability measurements will include:  
• Physical examination  
• Vital signs, including monitoring of blood pressure , pulse and heart rate  
• Blood samples will be collected for hematology, clinical chemistry, coagulation 
parameters  and thyroid function tes ts 
• Adverse events  
12.2.[ADDRESS_194286] -study drug.  In addition, 12 lead 
ECGs will be used to confirm any persistent arrhythmias  at the following time points:  
• [ADDRESS_194287] -study drug  
• [ADDRESS_194288] -study drug  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 43 of 61 12.2.2  Biochemistry  
Samples will be analyzed for s odium, potassium, chloride, bicarb onate, glucose, urea, urate, 
creatinine, phosphate, total and, albumin, total protein, total and conjugated bilirubin, GGT, 
alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate transaminase (AST), 
lactate dehydrogenase (LD), TSH, T3 and fr ee T4  at the time points listed below:  
• Pre-study drug  
• 4, 12, [ADDRESS_194289] (during anticoagulant administration only) hemoglobin, red 
blood cell count (RBC), packed cell volume (PCV), mean corpu scular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
platelets, white cell count (WCC), and absolute counts of neutrophils, lymphocytes, monocytes, 
eosinophils and basophils  at the time points listed bel ow: 
• Pre-study drug  
• 4, 12, [ADDRESS_194290] -study drug  
12.2.4  Troponin Levels  
In order to calculate AUC 0 -48 hours, s erum troponin T levels will be measured at  the following 
time points:  
• Pre-study -drug 
• 12, 24, [ADDRESS_194291] -study drug  
12.2.5  Other Biomarkers of Cardiac Injury and Inflammation  
Serum biomarkers of cardiac injury , inflammation  and remodeling  will be measured  at the 
following time points:  
• Pre-study drug  
• 1,4,12, [ADDRESS_194292] -study drug  
• [ADDRESS_194293] used in this trial will be obtained from the relevant laboratory performing trial tests. In the 
event the clinical laboratories are changed during the trial, Faraday Pharmaceuticals, Inc. will be 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 44 of 61 promptly notified of  the reason and date of the change and appropriate documentation will be 
submitted to verify the certification of the new laboratory.  
All clinical laboratory tests will be conducted at the investigational site’s local laboratory. All 
accreditation certifi cates and laboratory reference ranges will be obtained prior to the 
commencement of the trial at the investigational site.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 45 of 61 13 SAFETY: ADVERSE EVEN TS 
13.1 Definitions  
An Adverse Event (AE)  is defined as any untoward medical occurrence in a subject, or clinical 
investigation subject administered an investigational product (pharmaceutical) and which does 
not necessarily have a causal relationship with this treatment. An AE can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding),  symptom, or 
disease temporarily associated with the use of a medicinal (investigational) product, whether or 
not related to the investigational product. A relationship to the investigational product is not 
necessarily proven or implied.  
All adverse event s occurring after a dose of investigational product observed by [CONTACT_86183] (whether or not attributed to investigational product), will be reported 
on the case report form.  
Given that this study specifically recruits STEMI  patients, the MI itself will not be 
characterized as an AE.  
However, complications arising as a consequence of the MI, for example emergent or 
worsening heart failure, death, or  known  arrhythmias will be specifically documented as 
adverse events in the CR Fs.  
Adverse events will be followed until resolved or considered stable  out to 3 months . The only 
serious adverse event that will be tracked longer than 3 months is the i ncidence of death. All -
cause mortality and cardiac -related mortality will be document ed by [CONTACT_167124] 6 
months.  If the patient is unavailable, then mortality status will be obtained through 
physician/investigator records. The following attributes must be assigned by [CONTACT_093]:  
description; dates of onset and reso lution; severity; assessment of relatedness to investigational 
product, other suspect drugs, and action taken.  The investigator may be asked to provide follow -
up information.   
13.2 Relationship to Study Drug  
The principal investigator ( PI) will classify every AE according to its relationship to study drug 
or trial -related procedures. The categories according to World Health Organization guidelines are 
listed in Table 3 . 
 
Table 3: Relationship of AE to Study Drug or Trial -Related Procedures  
Rating  Classification  Definition  
1 Probable  An AE that:  
• Occurs at a reasonable time interval after administration of the 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 46 of 61 study drug;  
• Follows a known response pattern to the study drug and;  
• Cannot be reasonably explained by [CONTACT_167125]’s  clinical state or by [CONTACT_43593][INVESTIGATOR_014]  
2 Possible  An AE that:  
• Occurs at a reasonable time interval after administration of the 
study drug;  
• Follows a known response pattern to the study drug, but;  
• Could have been produced by  [CONTACT_102]’s clinical state or by 
[CONTACT_43593][INVESTIGATOR_014]  
3 Unlikely  • An AE for which sufficient information exists to indicate that 
the etiology is unrelated to the study drug;  
• Another etiology is specified  
If the AE is classified as unlikely, the PI [INVESTIGATOR_167092] a likely cause, other illness, concomitant 
medication, or other.  
13.3 Intensity of Adverse Events  
The investigator will make an assessment of intensity for each AE and SAE reported during the 
study. The assessment will be based on the investigator’s cli nical judgment. The intensity of each 
AE and SAE recorded in the CRF should be assigned to one of the following categories:  
Mild:  An event that is easily tolerated by [CONTACT_423], causing minimal discomfort and not 
interfering with everyday activities.  
Moderate:  An event that is sufficiently discomforting to interfere with normal everyday 
activities.  
Severe:  An event that prevents normal everyday activities.  
An AE that is assessed as severe should not be confused with a SAE. Severity is a category 
utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.  
13.[ADDRESS_194294], regardless of the 
investigator or sponsor’s opi[INVESTIGATOR_167093] e relationship to investigational product.  
A serious adverse event is any untoward medical occurrence that at any dose:  
• Results in death  
• Is life -threatening  (NOTE: The term "life -threatening" in the definition of "serious" 
refers to an event/reaction in w hich the patient was at risk of death at the time of the 
event/reaction; it does not refer to an event/ reaction which hypothetically might have 
caused death if it were more severe)  
• Requires inpatient hospi[INVESTIGATOR_167094], Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 47 of 61 • Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Is a medically important event or reaction  
Medical and scientific judgment should be exercised in deciding whether reporting is appropriate 
in other situations, such as important medical events that may not be immediately life threatening 
or result in death or hospi[INVESTIGATOR_167095]. These 
should also usually be considered ser ious. Examples of such medical events include cancer, 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not resul t in hospi[INVESTIGATOR_602], or the development of drug 
dependency or drug abuse.  
Serious clinical laboratory abnormalities directly associated with relevant clinical signs or 
symptoms should also be reported.  
All SAEs occurring on study must be reported to the medical monitor within [ADDRESS_194295] ( IRB) of SAEs occurring at the site 
in accordance with local procedures, generally within 72 hours after knowledge of the SAE.  
The sponsor has a legal responsibility to notify the appropriate regulatory authorities about the 
safety of any tes t drug. Accordingly, prompt notification of any adverse events by [CONTACT_167126]. The reporting of SAEs will be conducted in accordance with 
International Conference on Harmonization (ICH) Good Clinical Practice (GCP) and local 
regulatory guidelines.  
The initial notification will include at least a description of the event, and the subject 
identification. This information should be supported as needed with written copi[INVESTIGATOR_110159], autopsy reports, and other document s when applicable on the SAE CRF or the site’s 
standard SAE form.  
All adverse events reported in this study will be coded using MedDRA. Treatment -emergent 
adverse events will be listed and summarized per treatment.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 48 of 61 14 STATISTICS  
14.1 Study Design  
This is a Phase 2A, Randomized, Double -Blind, Placebo -Controlled, Multi -Center Study of 
Intravenous FDY -5301 in Acute Myocardial Infarction  
14.1.1  General Approach/Considerations  
Missing observations will be excluded from the analyses; they will not be substituted by 
[CONTACT_167127]. 
Demographics will be tabulated and summarized by [CONTACT_9086] (mean, median, 
standard deviation, range) for continuous data and frequency tables for discrete data. Physical 
examination data from baseline and post -study and medical history d ata at baseline will be listed. 
All clinical safety and tolerability data will be listed for each subject. Hematology and clinical 
chemistry will be analyzed by [CONTACT_167128].  Laboratory values outside the 
laboratory’s reference ranges a nd associated repeat values together with comments as to their 
clinical significance will be listed separately. Adverse event data will be summarized by [CONTACT_19313], 
visit, severity, and relationship to the study drug.  
All adverse events reported in this study w ill be coded using MedDRA [ADDRESS_194296] pharmacokinetic parameters will be  calculat ed for blood iodide levels.  
14.1.2  Populations  
The safety population includes all subjects who were randomized and received any amount of 
study drug. Subjects who did not receive any study medication will not be included in the safety 
population.  
The intent -to-treat (ITT) population will include subjects who gave informed consent and were 
randomized. This is the “full analysis set” of subjects.  Subjects are included in the ITT 
population according to the treatment assigned.  
The per protocol population will be a subset of the ITT population and will include subjects who 
gave informed consent, were randomized, received any amount of study drug, underwent PCI, 
and underwent an MRI at 72 +/ -[ADDRESS_194297] -study drug . These 
arrhythmias including vent ricular fibrillation, sustained  ventricular tachycardia  (≥125 BPM, ≥ 30 
seconds), non-sustained ventricular tachycardia (≥ 125 BPM, ≥ 16 beats, < 30 seconds) and high 
degree AV block ( 2nd or 3rd degree, ≥ 8 beats) were chosen because they are significant 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 49 of 61 prognostic indicators of depressed left ventricular ejection fraction and cardiac death [ 1]. The 
combined number of arrhythmic events in each group will be calculated along with the 
arrhythmia incidence rate defined as the percentage of patients in each gr oup experiencing at 
least one of the defined arrhythmias of interest.  
An exploratory sub -analysis will be conducted to determine the number and incidence rate of 
each separate arrhythmia type per dose group.  
Secondary exploratory e fficacy outcomes will include : 
Infarct size as a proportion of ventricular volume ( INF/VV), the myocardial salvage index 
(MSI) , absolute MI size ( INF) at 72 +/ - [ADDRESS_194298] differences across 
treatment groups.     
Estimating a drop -out rate of approximately 5 0%, we will need to enroll up to 1 60 patients in 
order to obtain a final total  sample size of 80 pat ients . A final sample size of 80 patients will 
provide  80% power to detect a 37% reduction  in INF/VV assuming an SD of 10%, a 24% 
increase in MSI assuming an SD of 20% and a 39% reduction in Troponin AUC with an SD of 
60%. Equal variance was assumed among groups with an unbalanced allocation of patients to 
placebo (n=20) and combined FDY -5301 treatment groups (n=60).  
14.1.5  Interim and Final Analyses  
After the 14 day follow up visit to the clinic, all subjects’ data will be collected and analyzed for:  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 50 of 61 • Safety (14 -day arrhythmias)  
• Early efficacy outcomes including MSI, INF/VV, INF  
• Serum troponin AUC [ADDRESS_194299] study drug  
• ST-segment resolution by [ADDRESS_194300] -study drug  
• Cardiac function including EDV, ESV, FS and EF  
After the 3 month follow up visit, analysis of  the following will occur:  
• Early efficacy outcomes including MSI, INF/VV, INF  
• Cardiac function including EDV, ESV, FS and EF  
All remaining assessments will be analyzed at the conclusion of the study.  
14.1.6  General Analysis of Safety and Efficacy Outcomes  
Analysis of the primary safety outcome: characterize the number and incidence  rate of serious 
arrhythmias that occur during a 14 -day interval in this patient population.  No hypothesis will be 
tested and data will be descriptive in nature only.  A more det ailed analysis strategy will be 
outlined in the SAP.  
Analysis of exploratory secondary efficacy outcomes:  For  all variables with a continuous 
outcome including infarct size relative to the VV, MSI, absolute MI size, cardiac function, 
biomarkers of cardiac injury and cardiac troponin levels , a single pairwise comparison to analyze 
difference s between all three FDY -5301 groups (combined) and placebo  will be used . An 
unpaired Student’s T test will be used for the pairwise comparison if th e data are normally 
distributed and a Mann -Whitney rank test will be used for nonparametric data. Each group will 
then be tested using a one -way analysis of variance (ANOVA) to obtain a common variance 
followed by  a Dunnett’s post -test to separately compar e each FDY -[ADDRESS_194301]. Laboratory values  will be calcula ted as group mean data and 
presented in shift tables. Comments as to the clinical significance of out of range values will be 
listed separately. Adverse event  data will be summarized by [CONTACT_19313], visit, severity, and possible 
relationship to the study drug.  
14.1.7  Pharmacokinetic Data Analysis  
The concentration of iodide in blood (at different time points and doses) will be summarized for 
each group. The pharmacokinetic analysis will include collections of a concentration -time profile 
in subjects following dosing wit h study drug. Mean, standard deviation (SD) and CV will be 
calculated at each time point. The pharmacokinetic behavior of blood iodide will be described as 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 51 of 61 area under the concentration versus time curve (AUC, AUC inf) the maximal concentration (C max), 
the time when the maximal concentration is achieved  (Tmax), the apparent terminal elimination 
rate (Kel) and terminal half -life (T 1/2) for each subject. From this information, the total body 
clearance (CL), and the volume of distribution (V) will be derived.  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 52 of 61 15 ACCESS TO SOURCE DATA /DOCUMENTS  
15.[ADDRESS_194302] of the Study  
The study will be conducted according to the principles of the World Medical Association’s 
Declaration of Helsinki and the ICH guidelines for GCP.  Faraday will ensure that the study 
complies with  all local, federal or country -specific regulatory requirements.  
The Investigator must ensure the anonymity of all subjects participating in the study. Each 
subject will be assigned a unique subject identification number that should be used on all forms 
associated with the subject’s samples or documents that will be supplied to the Sponsor (or 
CRO) or to any party completing testing on behalf of the Sponsor (e.g., samples for central 
laboratory analyses). Data privacy will be maintained according to local a nd federal 
requirements and will not be released without the written permission of the subject (or the 
subject’s guardian), except as necessary for mon itoring and auditing by [CONTACT_92092] , its designee, the 
FDA or other applicable regulatory authority, or the I RB/IEC.  
All unpublished information concerning the study drug, as well as any information concerning 
the busine ss or operations of Faraday Pharmaceuticals  or its affiliates that have been provided by 
[CONTACT_167129] r and all employees and coworkers 
involved with this study (“Study Personnel”), are c onfidential and will remain confidential 
informati on and sole property of Faraday . This includes, without limitation, information 
concerning the clinical indications for t he study drug, its formula, methods of manufacture, 
regulatory, marketing and strategic information, and all other scientific, nonclinical or clinical 
data relating to it. Study Personnel must agree to use the information only for the purposes of 
carrying out this study and for no other purpose unless prior written permission is obtained from 
Sponsor’s authorized representative, and not to disclose, or use Sponsor’s confidential 
information for any purpose other than performance of the study. Prior written agreement from 
the Sponsor’s authorized representative must be obtained for the disclosure of any said 
confidential information to  other parties.  
 
15.[ADDRESS_194303] periodic on -site visits.  
During these on -site visits, the monitor will:  
• Review study progress  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 53 of 61 • Review study data collected  
• Conduct source documentation verification  
Data recorded on subject’s CRF will be source document verified by [CONTACT_11200]. CRFs 
will be forward to the contracted Data Management group and data entered, verified and 
corrected according to the Statistic al Analysis Plan.  
The subjects’ CRFs and supporting documents will be reviewed and confidentiality will be 
maintained at all times. Direct access source data verification (SDV) will occur in this trial. 
Parameters checked for 100% of subjects entered into the trial will include, but not be limited to, 
the following:  
• Subject ID number and initials  
• Date of birth  
• Presence of signed informed consent  
• Gender  
• Eligibility criteria  
• Concomitant medication  
• Visit dates  
• Adverse events  
• Compliance with drug admini stration  
• Key safety variables  
The investigator agrees to allow the study monitor direct access to all relevant study -related 
documents and to set aside time to discuss any relevant findings or issues.  
Study closure will involve the following activities w ith site staff and investigator(s):  
• Return of all study -related material to the sponsor  
• Resolution of outstanding data queries  
• Accountability, reconciliation and arrangements for unused investigational product  
• Review of site study records for completeness  
15.[ADDRESS_194304] (IRB) / Independent Ethics Committee (IEC)  
Federal regulations and the ICH guidelines require that approval be obtained from an IRB/IEC 
prior to participation of human subjects in research studies. Prior to the study onset, the p rotocol, 
informed consent, advertisements or materials to be used for subject recruitment, and any other 
written information to be provided to the subject must be approved by [CONTACT_1201]/IEC. Any 
amendment s to the protocol or informed consent will require review and approval by [CONTACT_5040]/IEC  before the changes are implemented to the study . Documentation of all IRB/IEC 
approvals and of the IRB/IEC compliance with ICH Guideline E6 will be maintained by [CONTACT_167130].  
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 54 of 61 All IRB/IEC approvals should be signed by [CONTACT_1201]/IEC chairman or designee and must identify 
the IRB/IEC name [CONTACT_3816], the clinical protocol by [CONTACT_29985]/or protocol number, and the date 
that approval and/or a favorable opi[INVESTIGATOR_11744].  
The Principal Investigator [INVESTIGATOR_167096] 1 year or as otherwise specified by [CONTACT_5040]/IEC. The Principal Investigator [INVESTIGATOR_54720] -Investigator must supply Faraday  or its designee 
with written documentation of continued review of the clinical research.  
The IRB/IEC is expected to maintain the confidentiality of the protocol and related information.  
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194305] ensure that all trial -
related site source data, study -related documents, and reports will be made available for 
inspection by [CONTACT_167131]/EC/IEC.  
The Investigator is responsible for notifyin g Faraday  in advance of an impending regulatory 
inspection. He/she may request that Faraday  provide support for preparation, if necessary, and is 
required to provide updates on the ongoing activities during the inspection and submit any 
citations/objection able findings (i.e., FDA 483) and is required to share any follow up responses 
to the outcome.  
Accurate and reliable data collection will be assured by [CONTACT_89836] -check of the 
eCRFs against the Investigator’s records by [CONTACT_39613] (sourc e document verification). 
The Monitor will also review the Investigator’s drug accountability records to ensure that the 
drug supplies are stored and dispensed appropriately. A comprehensive validation program will 
verify the data and queries will be gener ated for resolution by [CONTACT_737]. Throughout the 
study, Faraday  or its  designates may review data as deemed necessary.  
 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 56 of 61 17 INFORMED CONSENT  
 
A written informed consent in compliance with Part 50 of Title 21 of the Code of Federal 
Regulations (CFR), wit h the Declaration of Helsinki, ICH guidelines, federal and/or local 
regulations, and advance approval by [CONTACT_4707] (IRB)/Ethics Committee 
(EC)/Independent Ethics Committee (IEC) shall be obtained from each subject or a legally 
authoriz ed representative of the subject prior to entering the study or performing any unusual or 
non-routine procedure that involves risk to the subject, including washout of any medications.  
The decision of whether to obtain written consent directly from the subject will be determined by 
[CONTACT_093].  If, in the opi[INVESTIGATOR_871], the subject is not in a state to fully provide 
written consent, the investigator will obtain writt en consent from a legally authorized 
representative of the subject.  
Before enrollment, each prospective subject or legally authorized representative of the subject 
will be given a full explanation of the study and be allowed to read the approved informed 
consent form. Once the Principal Investigator [INVESTIGATOR_167097], the subject or legally authorized representative  of the subject will be asked to give 
consent to participate in the study by [CONTACT_1725].  
 If study informed consent was given by [CONTACT_423]’s legally authorized representative prior to 
study enrollment, the subject will be provided with a modified consent once they are stable (after 
investigational drug treatment and STEMI procedure) and in the opi[INVESTIGATOR_167098].  This modified informed consent document will cover the 
subject’s agreement  to remain in the clinical trial and proceed with all study related procedures 
and follow -up. 
 
The consent form s must be dated and retained by [CONTACT_167132]. The Investigator  will not undertake any investigation spe cifically required for the 
clinical trial until valid consent has been obtained. The terms of the consent and when it was 
obtained must also be documented in the CRF.  Each subject will receive a fully -signed copy of 
each consent form that he/she signs for the clinical trial  
The Principal Investigator [INVESTIGATOR_167099].  
If any institution -specific modifications to study -related procedures are proposed or made by [CONTACT_39722], the consent should be reviewed by [CONTACT_1052]/or its designee, if appropriate, prior to 
IRB/IEC submission. Once reviewed, the consent will be submitted by [CONTACT_079] 
[INVESTIGATOR_167100]/IEC for review and appro val prior to the start of the 
study. If the informed consent form is revised during the course of the study, all actively 
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194306]’s partner , becomes pregnant during their participation in the trial, a separate 
pregnancy  informed consent form will be obtained , to follow the pregnancy, any complications, 
and the health of the baby.  The pregnancy consent should  be obtained at the time th e 
investigator becomes aware of the pregnancy.  
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194307]’s source 
documentation any deviation from the approved protocol. A deviation from the protocol is an 
unintend ed and/or unanticipated departure from the procedures and/or processes approved by [CONTACT_11707]/IEC and agreed to by [CONTACT_079]. Protocol violations and 
deviations will be documented by [CONTACT_135786]. 
Principal Investigator [INVESTIGATOR_167101]/or deviations in writing by [CONTACT_2037]. 
The IRB/IEC should be notified of all protocol violations and deviations according to IRB/IEC 
reporting requirements.  
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194308] essential information in the medical records in 
accordance with local regulations and requirements. The Investigator is responsible for ensuring 
the accu racy, completeness, legibility and timelines of the data recorded in the eCRF.  
The Principal Investigator [INVESTIGATOR_167102] 
(eCRFs). These source documents are distinct from the eCRFs and are designed to record all 
observations and other data pertinent to the investigation on each subject .  
The eCRFs will be reviewed and the source documents verified by [CONTACT_167133], in accordance with the Clinical Monitoring Plan, to ensure that data in 
the eCRFs are accurate and complete.  
19.[ADDRESS_194309]. These documents should be retained for a 
longer period, however, if required by [CONTACT_167134] .  
Faraday  will notify the Investigator/institution when the study records are no longer needed.  
If the Investigator withdraws from the study (e.g., relocation, retirement), the records must be 
transferred to a mutually agreed upon designee (e.g., another investigator, IRB). Not ice of such 
transfer will  be given in writing to Faraday .  
The Investigator must inform Faraday immediately if any documents are lost, to be transferred to 
another facility, or to be transferred to a different owner.  
The I nvestigator must contact [CONTACT_167135].  
19.3 Confidentiality and Publications  
All clinical trial  findings and documents will be regarded as confidential. The Investigator  and 
members of his/her research team must not disclose such information without prior written 
approval from the Sponsor.  
The anonymity of participating subjects must be maintained. Subjects will be identified on CRFs 
and other documents by [CONTACT_139927], initials and/or birth date, not by [CONTACT_167136] . Documents not to be submitted that identify the subject 
(e.g., the signed informed consent) must be maintained in confidence by [CONTACT_737] .  
Faraday Pharmaceuticals, Inc.,   
FDY -[ADDRESS_194310] meet each 
of the following 3 criteria:  
 Substantial contribution to conception and design or acquisition of data, or analysis and 
interpretation of data  
 Drafted the article or revised it cri tically for important intellectual content  
 Approved the final version for publication  
Members of the study steering committee generally fulfill the authorship criteria through their 
involvement in protocol design and review, monitoring of and sometimes dir ect involvement 
with recruitment, and thus they will usually be part of the publication committee. If studies are 
multicenter, it may be appropriate to assign group authorship.  
In addition, certain Faraday employees involved in the design and conception of  the protocol, 
study management and data analysis and interpretation are qualified authors and will be included 
in the publication committee e.g., the lead physician, statistician and study project manager or 
their equivalents.  
 
. 
Faraday Pharmaceuticals, Inc.,   
FDY -5301  Clinical Study Protocol  
 
Confidential , FDY -5301 -201-US Page 61 of 61 20 REFERENCES  
 
1.  Poul Erik  Bloch Thomsen, MD; Christian Jons, MD; M.J. Pekka Raatikainen, MD;  
Rikke Moerch Joergensen, MD; Juha Hartikainen, MD; Vesa Virtanen, MD; J. Boland, MD; Olli 
Anttonen, MD; Uffe Jakob Gang, MD; Nis Hoest, MD; Lucas V.A. Boersma, MD; Eivin S. 
Platou, MD; Dan iel Becker, MSc; Marc D. Messier, PhD; Heikki V. Huikuri, MD; (2010) . Long -
Term Recording of Cardiac Arrhythmias With an  Implantable Cardiac Monitor in Patients With 
Reduced  Ejection Fraction After Acute Myocardial Infarction  The Cardiac Arrhythmias and Ri sk 
Stratification After Acute Myocardial Infarction (CARISMA) Study. Circulation . 121:1258 -
1264. DOI: 10.1161/CIRCULATIONAHA.109.902148  
 
 
 